Myosin Therapeutics Inc.
MT-110, a selective nonmuscle myosin II inhibitor therapeutic for methamphetamine use disorder
- Sector
- Biotech
- Headquarters
- FL
- Founded
- 2020
- Latest Form D
- $1.5M, Dec 2022
- Total capital
- $14.4M
- Federal grants
- $12.9M
- 11 awards · 2021–2025
- Rank in peer group#37 of 514
- Private capital raised
- $1.5M
- 1 Form D · last Dec 2022
- 46 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- None on recordNo USPTO grants. Applications publish after 18 months.
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Phase 0/I dose escalation trial of MT-125 monotherapy in recurrent high-grade gliomas$2.2M
- Federal grantHealth and Human S · Phase II · Phase 0/1b Clinical Trial of Novel Therapeutic Agent MT-110 for the Reduction of Methamphetamine Use - Part 2$1.5M
- Federal grantHealth and Human S · Phase II · MT-125 for the Therapeutic Treatment of Glioblastoma$911K
- Federal grantHealth and Human S · Phase II · MT-125 for the Therapeutic Treatment of Glioblastoma$1.3M
- Federal grantHealth and Human S · Phase II · Development of a first-in-class nonmuscle myosin II inhibitor to prevent substance use disorder relapse$1.2M
- Federal grantHealth and Human S · Phase II · Development of a first-in-class nonmuscle myosin II inhibitor to prevent substance use disorder relapse$441K
- Federal grantHealth and Human S · Phase I · MT-125 for the Therapeutic Treatment of Glioblastoma$407K
- Private capital raisedForm D · SEC · 1st filing$1.5M
Show 4 earlier federal awards
- Federal grantHealth and Human S · Phase II · MT-125 for the Therapeutic Treatment of Glioblastoma$407K
- Federal grantHealth and Human S · Phase II · Development of a first-in-class nonmuscle myosin II inhibitor to prevent substance use disorder relapse$2.9M
- Federal grantHealth and Human S · Phase II · Development of a first-in-class nonmuscle myosin II inhibitor to prevent substance use disorder relapse$1.2M
- Federal grantHealth and Human S · Phase II · Development of a first-in-class nonmuscle myosin II inhibitor to prevent substance use disorder relapse$325K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
15months
from Myosin Therapeutics Inc.’s first federal award to its first private round.
- First federal award · Sep 2021
- Health and Human S · $325K
- First Form D · Dec 2022
- $1.5M · 1st Form D
- Awards before first raise
- 3 awards
An association in public records, not a cause or a prediction.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#37 · top 7%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Andrew RitterDirectorNamed in SEC Form D filings
- Courtney MillerExecutive Officer, DirectorNamed in SEC Form D filings
- Dave AdamsDirectorNamed in SEC Form D filings
- Jackson StreeterDirectorNamed in SEC Form D filings
- Patrick Griffin, Ph.D.DirectorNamed in SEC Form D filings
- Robert FinizioDirectorNamed in SEC Form D filings
Show all 7 people
- Theodore KameneckaDirectorNamed in SEC Form D filings
What it has protected
No granted patents are on record.
USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.
Checked: USPTO granted patents and published applications · Oct 23, 2026
Related companies, and why
- Transtarget IncSimilar federal contract value in Biotech · null in contracts
- RESILIO THERAPEUTICS, LLCSimilar federal contract value in Biotech · null in contracts
- IMMvention Therapeutix, Inc.Similar federal contract value in Biotech · null in contracts
- Applied BioMath, LLCSimilar federal contract value in Biotech · null in contracts
- Obatala Sciences, Inc.Similar federal contract value in Biotech · null in contracts
- Qlaris Bio, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .